Title : Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.

Pub. Date : 2017 Mar

PMID : 28138868






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 A synergistic interaction was observed for combination treatment with RK-33 and the PARP inhibitor olaparib in BRCA1-proficient breast cancer, with the mean combination index ranging from 0.59 to 0.62. olaparib collagen type XI alpha 2 chain Homo sapiens